Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ONCT - Oncternal Therapeutics Inc
-0.11(-3.49%)6:00:00 PM 11/26/2021
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. The company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ROR1) that is in Phase I/II clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in Phase Ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. It also develops TK-216, a small-molecule that is designed to inhibit E26 transformation specific family of oncoproteins, which is in Phase I clinical trial to treat patients with Ewing sarcoma and in combination with vincristine chemotherapy. In addition, the company develops a chimeric antigen receptor-T product candidate that targets ROR1, which is in preclinical development for treating hematologic cancers and solid tumors. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics

Related Peers

Stock news